Coexpression network analysis identified lncRNAs-mRNAs with potential relevance in African ancestry prostate cancer

Rafael Parra-Medina¹,²,³*, Liliana López-Kleine⁴, Sandra Ramírez-Clavijo¹ & César Payán-Gómez*,¹

¹Faculty of Natural Sciences, Universidad del Rosario, Bogotá, Colombia
²Department of Pathology, Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia
³Department of Pathology, Instituto Nacional de Cancerología, Bogotá, Colombia
⁴Department of Statistics, Faculty of Science, Universidad Nacional de Colombia, Bogotá, Colombia

*Author for correspondence: cesar.payan@urosario.edu.co

Aim: This study aims to investigate similarities and differences using IncRNA and mRNA coexpression network analysis in African ancestry (AA) and European ancestry (EA) among prostate cancer (PCa) patients.

Methods: We performed weighted gene coexpression network analysis of the expression from 49 of AA and 49 of EA to identify lncRNAs-mRNAs.

Results: 27 lncRNAs and 36 mRNAs were highly expressed in patients of AA. Two mRNAs and their antisense lncRNAs were expressed. Additionally, seven mRNAs were DE or coexpressed and had an impact on survival.

Conclusion: We present a list of lncRNAs and mRNAs that were DE and coexpressed when comparing patients of AA and EA, and these data are a resource for future studies to understand the role of lncRNAs.

Lay abstract: This research demonstrated differences among AA and EA PCa patients. 27 IncRNAs and 36 mRNAs were highly expressed in patients of AA. 24 mRNAs were coexpressed with at least one IncRNAs. Seven mRNAs (CENPN, DNAAF3, DNASE1L2, PCDHB2, PCSK6, RTN4RL2, THBS4) were upregulated, respectively. In addition, the pathway enrichment analysis revealed two interesting signaling pathways (MAPK and Wnt) that are involved in oncogenesis and are exclusively involved in patients of AA. In summary, this study provides a resource for future investigation of the role of lncRNAs and coexpressed genes in patients of AA and EA.

First draft submitted: 5 June 2021; Accepted for publication: 30 July 2021; Published online: 24 September 2021

Keywords: African • ancestry • coexpression • IncRNA • mRNA • prostate cancer

Prostate cancer (PCa) is the most common tumor in men and the fifth-leading cause of cancer-related death around the world [1]. The incidence, clinical presentation and mortality of PCa vary according to race/ethnicity [2]. Globally, an increased number of PCa cases has been observed in men of African ancestry (AA) [2,3]. In the USA, African–American men are more likely to present at an earlier age, have developed advanced or metastatic PCa at diagnosis and have suboptimal outcomes after standard treatment [4,5]. Aspects related to patients, such as knowledge of the disease, low education, healthcare utilization, socioeconomic factors and genetic predisposition, have been associated with this elevated incidence [4,6].

Genetic alterations, such as mutations, changes in copy number, fusion of genes, changes in gene expression and abnormal splice variants, have been reported in PCa patients of AA [7]. In a recent study performed by Yuan et al. [8], through an integrative comparison of genomic and transcriptomic differences, significant differences were found between AA and European Ancestry (EA) patients. The most relevant differences were SPOP mutations (20.3% AA patients vs 10.0% EA patients), TMPRSS2-ERG fusions (29.3% AA patients vs 39.6% EA patients), PTEN deletion/losses (11.5% AA patients vs 30.2% EA patients), significant enrichment of eQTL target genes between patients of AA and EA and high expression of genes associated with immune-related pathways and PTEN/PI3K signaling in patients of AA compared with patients of EA.
The products of the human transcriptome are coding RNAs or noncoding RNAs (ncRNAs). Coding RNAs are templates used to organize the amino acids that constitute proteins during the translation process, and their structure and function are well known. Furthermore, based on their sizes, ncRNAs are classified as small ncRNAs (ncRNAs; <200 bp) and long ncRNAs (lncRNAs; >200 bp). Small ncRNAs are 20 to 30 bp in length, and based on structure/functionality, they are subdivided into cis regulatory (internal ribosome entry site [IRES], Leader, Riboswitch), gene (rRNA, tRNA, snRNA/snoRNA, miRNAs, among others) and intron sequences (Groups I and II) (9,10). In medicine, miRNAs are of great interest because their expression constitutes a molecular fingerprint of different types of tumor cells, and they are possible candidates for treatment targets. miRNAs also play roles in gene expression by activating transcription (11) or inhibiting translation (12).

On the other hand, lncRNAs are classified as circular (circARN) or linear according to their structure. circRNAs are a type of single-stranded RNA that are generated by the formation of a loop in the primary pre-mRNA transcript due to back-splicing of an exon and/or intron, and the circle is closed by a covalent bond that makes it less susceptible to exonucleases. circRNAs regulate the expression of target genes during transcription and splicing as inhibitors of miRNAs, and circRNAs modulate the function of proteins by acting as decoys and encoding functional peptides (13). In addition, linear lncRNAs are classified based on genomic localization relative to protein-encoding genes. These groups are sense, antisense, bidirectional, intronic, intergenic 3′ overlapping, macro ncRNA, process transcripts and enhancer lncRNAs (9,10). LncRNAs are involved in different cellular processes, such as maintaining nuclear structure integrity, positively or negatively regulating gene expression by recruiting transcription factors and/or chromatin remodelling complexes to DNA targets, regulating RNA splicing, acting as decoys to sequester RNA-binding proteins (RBPs) and sequestrating miRNAs (miRNA sponges) (14,15).

Dysregulation of miRNAs and lncRNAs is widely observed in the pathogenesis of different cancer types, and these RNAs are mainly involved in tumor growth, invasion and metastasis (16–18). LncRNAs are easily obtained for study from tissues and body fluids due to their resistance to degradation. These two types of ncRNAs are good candidate biomarkers with effects on the clinical diagnosis, prognosis and treatment of cancer. In recent years, numerous preclinical and early clinical studies have explored lncRNAs as new therapeutics (19).

In PCa, numerous miRNAs are involved in different processes that promote prostate oncogenesis, such as the cell cycle, apoptosis, epithelial–mesenchymal transition (EMT), DNA replication/repair, migration, androgen receptor suppression, metastasis and treatment resistance (20–22). IncRNAs have also been shown to be dysregulated and associated with the pathogenesis and progression of PCa (14,18,23). In a recent review published on the past 30 years, Ramnarine et al. (23) found 109 IncRNAs associated with PCa. These IncRNAs are involved in the migration and proliferation of tumoral prostate cells in different stages of disease, such as localized disease, metastatic disease or castration-resistant PCa. The molecular mechanisms targeted by these lncRNAs in PCa pathogenesis were grouped into transcriptional regulation (epigenetic modification, transcriptional activation, transcriptional inhibition, RNA decay), post-transcriptional regulation (regulation of antisense RNA, translational regulation, mRNA stabilization, miRNA host, miRNA sponge) and posttranslational regulation (subcellular structure, protein transport, protein complex mediation). In PCa, several IncRNAs have been proposed as biomarkers because they favor both carcinogenesis and tumoral progression (24). In the present study, a systems biology analysis was conducted to identify similarities and differences using lncRNA and mRNA coexpression network analysis.

Materials & methods

Data collection

The data provided by TCGA and processed for reuse by recount2 (25) were used as a primary source for data analysis. Gene counts for all prostate cancer and normal prostate tissues were downloaded. Samples annotated as having African and European ancestry by Yuan et al. (8) were selected. Finally, we kept all tumor samples from patients of AA, and we selected the same number of samples from patients of EA. These samples were randomly matched 1:1 (AA vs non-AA), taking into account the Gleason score obtained from the clinical information registered in The Cancer Genome Atlas Program (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) as a parameter.

Data preprocessing

The transcriptomic data (mRNA and lncRNA) available in recount2 (25) were already processed with Rail-RNA as described in recount2 (25). We performed quality control of all datasets to identify that the samples we selected had a similar distribution after and before normalization by the use of density plots and box plots. Additionally, we
plotted a multidimensional plot, and we performed a visual evaluation of the localization of the samples in the first four dimensions.

### Identification of differentially expressed RNAs

The gene count data of each kind of RNA in patients of AA and EA were analyzed independently on the Galaxy web platform \[26\]. Data were normalized by library sizes using the trimmed mean of M-values (TMM) method. Genes without more than 1 count per million mapped reads (CPM) in at least 50% of the samples were considered not expressed and were filtered out. The limma-voom method was used to identify the differentially expressed (DE) genes. The primary factor was normal versus tumor, and the second factor was the Gleason score of the samples. An mRNA or lncRNA was selected as DE if the linear fold change was higher than the absolute value of 2 and the false discovery rate (FDR) was lower than 0.01.

### Functional enrichment analysis of mRNAs with dysregulated expression

DAVID (https://david.ncifcrf.gov/) was used to identify the functions of the selected differentially expressed genes (DEGs). The upregulated and downregulated genes in each list of DEGs were analyzed separately. The Kyoto Encyclopedia of Genes and Genomes (KEGG) was chosen for overrepresentation analysis. Pathways with p-values lower than 0.05 were selected as enriched.

### Weighted gene coexpression networks analysis

The total levels of differentially expressed mRNAs and lncRNAs in tumor samples from patients of AA compared with normal samples were added to one list. Two coexpression networks were developed using this gene list. The first list was generated for patients of AA, and the second list was generated for patients of EA.

To build the coexpression networks, we followed a typical methodology. First, the similarity matrix was calculated by identifying the Pearson correlation coefficients of the expression levels for the samples based on all possible mRNA-mRNA, lncRNA-lncRNA and lncRNA-mRNA combinations. Then, the similarity threshold was calculated with the adjacency function, which was established according to the unique characteristics of each similarity matrix \[27\]. The method developed by Elo was used to select the threshold \[28\]. This method compared the tau values for the network grouping coefficient (Co) with those expected for a random network (Cr). It uses the clustering coefficient of the real graph in comparison to a random graph. The threshold for significant similarities is chosen so that the obtained real graph is scale-free. Finally, the adjacency matrix \((2 \times 2)\) of the network was established and allowed the representation of binary relationships. In this case, a pair of genes that exhibit coordinated gene-expression activity (coexpression) is indicated by (1); otherwise, a (0) is reported. All the weighted gene coexpression networks analysis (WGCNA) analyses were performed in an R unique environment using statistical functions (https://www.r-project.org/).

### Analysis of WGCNA

The WGCNA was plotted through network analysis using Cytoscape \[29\]. The identification of the differences between the AA and EA networks was calculated using the advanced network merge interface function implemented in Cytoscape.

### Survival analyses of differentially expressed genes among AA & EA & genes coexpressed with lncRNAs

Gene Expression Profiling Interactive Analysis (GEPIA; \[30\]) was used to calculate disease-free survival and overall survival between the DEGs coexpressed with lncRNAs. The lower and upper 50% of gene-expression levels were set as the standard for analysis. The confidence interval was 95%. High- and low-expression genes are represented in red and blue, respectively. Log-rank test results with \(p < 0.05\) were regarded as statistically significant.

### Results

#### Patient characteristics

In total, 98 PCa tissues, 49 in each group (AA and EA), and 44 normal prostate tissues (7 AA patient tissues and 37 EA patient tissues) were included. The mean age of the AA patients was 56.9 years, the mean age of the EA patients 58.8 years and the mean age of the patients from whom normal prostate tissue collected was 59.3 years. Each group included the same number of patients according to the Gleason score (GS). Nine patients had GS
Table 1. Number and direction of the change of differentially expressed mRNA and lncRNA in African ancestry and European ancestry.

|        | Total | Up  | Down |
|--------|-------|-----|------|
| mRNA   |       |     |      |
| TumorAA vs normal tissue | 2419 | 702 | 1717 |
| TumorEA vs normal tissue | 2296 | 600 | 1696 |
| TumorAA vs tumorEA | 8 | 5 | 3 |
| lncRNA  |       |     |      |
| TumorAA vs normal tissue | 1563 | 708 | 855 |
| TumorEA vs normal tissue | 1304 | 593 | 711 |
| TumorAA vs TumorEA tissue | 22 | 11 | 11 |

AA: African ancestry; EA: European ancestry.

Figure 1. Venn diagrams show the number of (A) DE mRNAs in AA and EA. (B) lncRNAs in AA and EA. AA: African ancestry; EA: European Ancestry.

3 + 3, 22 had GS 3 + 4, 11 had GS 4 + 3, 2 had GS 4 + 4, 2 had GS 4 + 5, 2 had GS 5 + 4, and 1 had GS 5 + 5. In the AA group, two patients were t2a, two were t2b, 22 were t2c, 14 were t3a, and 9 were t3b, while in the EA group, two patients were t2a, 29 were t2c, 11 were t3a, 5 were t3b, and two had no information. In the AA group, 7 were n1, 36 were n0, and 6 had no information; in the EA group, 5 were n1, 29 were n0, and 15 had no information. Only two patients died in each group. Supplementary Table 1 shows all clinical data information for the 98 PCa patients and 44 normal prostate tissues obtained from TCGA.

Identification of differentially expressed lncRNAs & mRNAs
All the samples had adequate quality control parameters, and all of them were used for additional analysis. A total of 2419 mRNAs were differentially expressed (DE) in prostate tumor tissue samples compared with normal prostate tissue samples in PCa patients of AA. Additionally, 2296 DE mRNAs were detected in PCa patients of EA. The same analysis was performed for the gene counts of lncRNAs, and 1563 and 1304 lncRNAs were detected as DE in the tissues from patients of AA versus the normal tissues and in the tissues from patients of EA versus the normal patients, respectively. Additionally, we compared the transcriptomes of tumor samples from AA versus EA patients. The number of DE mRNAs and lncRNAs was small in the direct comparison between tumor samples from AA versus EA patients. Table 1 summarizes the number of DEGs in both comparisons.

Comparison of differentially expressed mRNAs & lncRNAs in AA & EA cancer prostate patient samples
To obtain a general overview of the similarities and differences in the transcriptomic deregulation of AA and EA prostate cancer patient samples, we compared the lists of DE mRNAs and lncRNAs. Figure 1 shows the number of DE mRNAs and lncRNAs in both groups of patients. Common differentially expressed genes had the same direction of change.
Table 2. mRNAs and IncRNAs differentially expressed between prostate cancer samples from patients of African ancestry and European ancestry.

| Gene ID           | Gene symbol | logFC | Adjusted p-value | Gene ID           | Gene symbol | logFC | Adjusted p-value |
|-------------------|-------------|-------|------------------|-------------------|-------------|-------|------------------|
| ENSG00000136883   | KIF12       | 1.66  | 0.0024           | ENSG00000274767   | AC243829.1  | 2.08  | 0.0003           |
| ENSG00000196436   | NPIPB15     | 1.61  | 0.0092           | ENSG00000259471   | LINC01169   | 1.95  | 0.0016           |
| ENSG00000244752   | CRYBB2      | 1.50  | 0.0024           | ENSG00000268181   | AC073188.6  | 1.91  | 0.0038           |
| ENSG00000182667   | NTM         | 1.42  | 0.0031           | ENSG00000269978   | AL359881.1  | 1.64  | 0.0038           |
| ENSG00000160973   | FOXH1       | 1.01  | 0.0060           | ENSG00000232283   | HSD1783-AS1 | 1.49  | 0.0088           |
| ENSG00000104490   | NCAID       | -1.05 | 0.0083           | ENSG00000275476   | AC009318.4  | 1.43  | 0.0016           |
| ENSG00000184058   | TBX1        | -1.28 | 0.0031           | ENSG00000271959   | AC100803.4  | 1.29  | 0.0073           |
| ENSG00000198785   | GRIN3A      | -1.53 | 0.0083           | ENSG00000262188   | LINC01978   | 1.25  | 0.0062           |
|                   |             |       |                  | ENSG00000261159   | AC112484.3  | 1.23  | 0.0003           |
|                   |             |       |                  | ENSG00000262877   | AC110285.2  | 1.20  | 0.0046           |
|                   |             |       |                  | ENSG00000232850   | PTGES2-AS1  | 1.20  | 0.0083           |
|                   |             |       |                  | ENSG00000253629   | AP000426.1  | -1.08 | 0.0029           |
|                   |             |       |                  | ENSG00000278936   | AC244517.4  | -1.08 | 0.0077           |
|                   |             |       |                  | ENSG00000277232   | GTE1-DT     | -1.09 | 0.0016           |
|                   |             |       |                  | ENSG00000182366   | FAM87A      | -1.19 | 0.0005           |
|                   |             |       |                  | ENSG00000250604   | AC098679.1  | -1.19 | 0.0005           |
|                   |             |       |                  | ENSG00000261357   | AC099518.2  | -1.30 | 0.0069           |
|                   |             |       |                  | ENSG00000279068   | AC244517.6  | -1.31 | 0.0046           |
|                   |             |       |                  | ENSG00000249159   | AC091965.1  | -1.45 | 0.0088           |
|                   |             |       |                  | ENSG00000279472   | AC244517.8  | -1.76 | 0.0003           |
|                   |             |       |                  | ENSG00000278472   | AC092668.2  | -2.92 | 0.0080           |
|                   |             |       |                  | ENSG00000271314   | AL161729.2  | -3.00 | 0.0027           |

Most DE mRNAs and IncRNAs were shared between prostate tumors from patients of AA and EA. For example, of 702 upregulated mRNAs in AA patients, 489 (69.7%) were shared with the upregulated mRNAs in EA patients. A similar result was obtained when the lists of IncRNAs were compared, following the same example: of the 708 DE IncRNAs in the samples from patients of AA, 472 (67%) of the genes were DE in common with the samples from patients of EA. Interestingly, the overlap between the lists of downregulated mRNAs and IncRNAs was even higher than that of upregulated genes. A total of 87.6% of the mRNAs and 74.2% of the IncRNAs upregulated in patients of AA were simultaneously upregulated in patients of EA.

To clarify the potential transcriptomic differences between prostate cancer samples from patients of AA and EA, we performed a direct comparison of those tumor samples. Table 2 shows the number of DE mRNAs and IncRNAs. There were only 8 mRNAs and 22 IncRNAs differentially expressed in the mentioned comparison.

Functional enrichment analysis of differentially expressed mRNAs
KEGG pathway enrichment analysis was then performed with the DE mRNAs observed in patients of AA and EA. Both groups presented similarities in the pathways evaluated among up- and downregulated genes. Five pathways were overrepresented among the upregulated genes of patients of AA and four pathways were overrepresented in patients of EA, and the pathway most enriched in both groups was systemic lupus erythematosus. Twenty-eight pathways were overrepresented among the downregulated genes of patients of AA and 24 in patients of EA, 21 of which were shared between patients of AA and EA. Two interesting pathways exclusively overrepresented in patients of AA were the MAPK and Wnt signaling pathways (Figure 2).
Figure 2. Pathway enrichment analysis for the differentially expressed between genes in patients of African ancestry and European ancestry (p < 0.05). (A) Enriched KEGG pathways for upregulated genes in AA. (B) Enriched KEGG pathways for upregulated genes in EA. (C) Enriched KEGG pathways for downregulated genes in AA (MAPK and WNT pathways). (D) Enriched KEGG pathways for upregulated genes in EA.

AA: African ancestry; EA: European Ancestry; KEGG: Kyoto Encyclopedia of Genes and Genomes.

Weight coexpression network analysis of DE mRNAs & lncRNAs in AA prostate cancer patient samples

Taking all of the previous results together, it was evident that there were few important differences in the transcriptomic deregulation of AA and EA. These differences are not sufficient to identify key molecular pathways related to the special clinical characteristics of AA prostate cancer patients.

We hypothesize that the combination of the lncRNA and mRNA expression profiles could be specific for each clinical group and that the differences could help to explain part of the differential clinical behaviour in prostate cancer patients of AA. Then, we performed a coexpression network analysis to identify critical networks of coexpressed lncRNAs-mRNAs in tumor samples from patients of AA.

First, we selected the DE mRNAs and lncRNAs in the comparison of tumor samples from patients of AA versus normal prostate samples. Second, using only the tumoral expression profiles, we calculated two coexpression networks, one for the 49 tumor samples from patients of AA and the other for the 49 tumor samples from patients of EA.

The AA network contained 224 nodes, 65 of them were lncRNA and 159 were mRNA. There were 68 pairs, six trios, two quartets, one quintet and four networks of more than eight nodes of co-expressed genes. Figure 3 shows the coexpression networks with more than five nodes as calculated with AA samples. While the EA network contained 203 nodes, 54 of them were lncRNA and 149 were mRNA. There were 52 pairs, six trios, two quartets, one quintet and three networks of more than eight nodes of co-expressed genes (Supplementary Figure 1).

We calculated the differences in the former network of coexpression of patients of AA with respect to the network of coexpression of patients with EA with the same mRNAs and lncRNAs but with the tumor samples from patients of EA.

The results of the network difference analysis indicated the specific relations of PCa patients of AA.
Figure 3. Co-expression network of DE mRNA and lncRNA in African ancestry tumor samples. lncRNA are marked in red and mRNA are marked in blue. Four networks with more than eight nodes of co-expressed genes are shown, one network co-expressed three lncRNA and another network co-expressed two lncRNA. Two tightly connected networks of the same family of genes (Protocadherin Alpha and TBC1 domain family member 3 [TBC1D3]). In the quintet network one lncRNA was co-expressed. One quartets network was with only lncRNA co-expressed. Among the five trios networks, two had two lncRNA co-expressed and the other only one. Small networks with fewer than two nodes are not shown.

Figure 4. Co-expression network of the differences between African ancestry less European ancestry networks. lncRNA are marked in red and mRNA are marked in blue. One network co-expressed three lncRNA and three network co-expressed one lncRNA. Most of the small networks with fewer than two nodes are not shown.

instances in which patients of AA showed reduced expression compared with patients of EA included 63 nodes, 27 of which were lncRNAs and 36 of which were mRNAs. There were 29 pairs, one trio and four subnetworks with at least six nodes (Figure 4). 24 mRNAs were coexpressed with at least one lncRNA. Seven mRNAs (CENPN,
Table 3. lncRNAs and mRNAs coexpressed in African ancestry.

| Gene ID   | lncRNA   | logFC | Adjusted p-value | Gene ID   | mRNA    | logFC | Adjusted p-value |
|-----------|----------|-------|------------------|-----------|---------|-------|------------------|
| ENSG00000180139 | ACTA2-AS1 | -2.51 | 1.53E-08 | Interact ENSG00000145936 | KCNMB1   | -2.79 | 2.84E-08 |
| ENSG00000180139 | ACTA2-AS1 | -2.51 | 1.53E-08 | Interact ENSG00000140682 | TGFB1I1  | -2.28 | 4.33E-07 |
| ENSG00000180139 | ACTA2-AS1 | -2.51 | 1.53E-08 | Interact ENSG00000196923 | PDLIM7   | -1.74 | 3.82E-06 |
| ENSG00000180139 | ACTA2-AS1 | -2.51 | 1.53E-08 | Interact ENSG00000198467 | TPM2     | -2.55 | 7.30E-09 |
| ENSG00000223774 | NA       | -3.09 | 3.41E-10 | Interact ENSG00000174099 | MSRB3    | -2.35 | 6.16E-09 |
| ENSG00000223774 | NA       | -3.09 | 3.41E-10 | Interact ENSG00000072864 | NDE1     | -2.94 | 1.19E-10 |
| ENSG00000230729 | NA       | -2.34 | 0.000161077 | Interact ENSG00000168913 | ENHO     | -1.95 | 0.002818634 |
| ENSG00000230937 | MIR205HG | -4.12 | 3.32E-06 | Interact ENSG00000186081 | KRT5     | -3.65 | 1.64E-06 |
| ENSG00000234405 | NA       | -2.86 | 3.36E-05 | Interact ENSG00000172476 | RAB40A   | -2.53 | 0.000185962 |
| ENSG00000234477 | NA       | -3.42 | 1.81E-05 | Interact ENSG00000108244 | KRT23    | -3.11 | 0.00196113 |
| ENSG00000234638 | NA       | -3.26 | 6.33E-10 | Interact ENSG00000163017 | ACTG2    | -3.19 | 7.14E-11 |
| ENSG00000249825 | CTD-2201I18.1 | 1.84 | 0.000143879 | Interact ENSG00000113296 | THBS4    | 2.22  | 0.000308678 |
| ENSG00000255301 | NA       | 1.37  | 3.50E-05 | Interact ENSG00000186907 | RTN4RL2  | 1.48  | 2.89E-06 |
| ENSG00000258451 | NA       | -1.80 | 4.42E-08 | Interact ENSG00000258818 | RNASE4   | -1.55 | 6.29E-08 |
| ENSG00000259018 | NA       | -2.68 | 7.19E-10 | Interact ENSG00000100842 | EFS      | -2.58 | 2.68E-08 |
| ENSG00000259172 | NA       | 1.27  | 0.000139358 | Interact ENSG00000140479 | PCSK6    | 1.30  | 4.98E-05 |
| ENSG00000259780 | NA       | 1.97  | 2.91E-08 | Interact ENSG00000167968 | DNASE1L2 | 2.00  | 3.32E-06 |
| ENSG00000260213 | NA       | 1.88  | 8.23E-07 | Interact ENSG00000166451 | CENPN    | 1.78  | 7.19E-06 |
| ENSG00000261707 | NA       | -1.29 | 7.90E-12 | Interact ENSG00000140876 | NUDT7    | -1.07 | 1.13E-08 |
| ENSG00000263065 | NA       | -3.47 | 2.78E-09 | Interact ENSG00000072864 | NDE1     | -2.94 | 1.19E-10 |
| ENSG00000263065 | NA       | -3.47 | 2.78E-09 | Interact ENSG00000095637 | SORB51   | -2.52 | 3.83E-09 |
| ENSG00000263335 | NA       | -3.38 | 6.01E-10 | Interact ENSG00000095637 | SORB51   | -2.52 | 3.83E-09 |
| ENSG00000267577 | NA       | 1.95  | 5.17E-06 | Interact ENSG00000167646 | DNAAF3   | 2.14  | 1.06E-06 |
| ENSG00000267601 | NA       | -1.75 | 2.90E-07 | Interact ENSG00000178404 | CEP295NL | -1.48 | 9.32E-05 |
| ENSG00000271894 | NA       | -2.84 | 3.66E-10 | Interact ENSG00000055813 | CCD5B5A  | -2.70 | 3.07E-07 |
| ENSG00000279047 | NA       | 2.15  | 0.00010411 | Interact ENSG00000112852 | PCDHB2   | 2.27  | 7.26E-06 |

Genes in bold are upregulated.

DNAAF3, DNASE1L2, PCDHB2, PCSK6, RTN4RL2, THBS4) were upregulated. THBSA4 and PCSK6 were coexpressed with their antisense IncRNAs, ENSG00000249825 and ENSG00000259172, respectively (Table 3).

Assessment of the prognostic significance of differentially expressed genes among patients of AA & EA & genes coexpressed with lncRNAs

Using GEPIA [30], which employed the PRAD dataset, the DE genes between tumors from patients of AA versus tumors from patients of EA (Table 2) and mRNA coexpressed with lncRNA in the AA-EA coexpression network (Figure 3) were identified. Among the DE genes that were associated with poor disease-free survival were FOXH1 (HR: 2.3; p: 0.0002), NTM (HR: 1.8; p: 0.009), and NPIPBP1 (HR: 1.7; p: 0.015) (Figure 5 A–C). Among the genes coexpressed in the network, patients of AA, to a lesser extent than those of EA, was associated with high expression of DNASE1L2 (HR: 2.2; p: 0.0003) (Figure 5 D), and poor disease-free survival, and low expression of RNASE4 (HR: 0.6; p: 0.019), NUDT7 (HR: 0.5; p: 0.011) and SORB51 (HR: 0.65; p: 0.047) served as protective factors for disease-free survival (Figure 5 E–G).

Discussion

In the present study, we observed subtle differences among PCa patients of AA and EA when we compared transcriptomic dysregulation focused on individual genes. Few DE mRNAs and IncRNAs were obtained in the comparison between the two populations. In the pathway enrichment analysis, some differences between the groups were observed. Two pathways exclusive to patients of AA were the Wnt and MAPK signaling pathways. Both pathways have been associated with PCa oncogenesis due to cellular activities, including cell proliferation, differentiation, survival, death and transformation [31,32]. Interestingly, these two pathways are involved in the...
The biosynthesis and metabolism of androgen have been observed in patients of AA [35]. Recent studies have provided evidence for a regulatory role for the AR signaling pathway in DE-lncRNAs. Variants of genes of the enzymes involved in both biosynthesis and metabolism of androgen have been observed in patients of AA [35].

Yuan et al. [8] observed high expression of DE mRNA-associated immune-related pathways in patients of AA and found a strong immune-related pathway [31,32] and regulation of the AR (androgen receptor) pathway [33,34]. The analysis was made in GEPIA.

Among the DE genes obtained by comparing patients of AA and EA, two upregulated genes (FOXH1 and NPIPB15) in patients of AA associated with poor disease-free survival were associated with the AR signaling pathway. FOXH1 is a member of the forkhead-box (FOX) gene family of transcription factors and participates in mediating transforming growth factor-β (TGF-β) signaling through its interaction with the Smad2-Smad4 complex [36]. FOXH1 may act as a co-repressor of AR [36]. On the other hand, NPIPB15 is a member of the nuclear pore complex-interacting protein family; however, its role in PCa is unknown. The nuclear pore complex promotes the progression of PCA by increasing POM121-driven E2F1, MYC and AR nuclear import [37].

We found 1563 DE lncRNAs expressed between tumoral tissue versus normal tissue in patients of AA. In the literature, the majority of DE lncRNAs are unstudied. Yuan et al. [8] also observed 1868 (11.7%) DE lncRNAs, and the majority were not studied. A total of 45.9% were classified as intergenic lncRNAs, which suggests that they are transcribed from protein-coding independent transcriptional units. Additionally, a high proportion of DE lncRNAs were observed in the nucleus, which indicates that they are probably involved in gene regulation at the transcriptional level.

Due to a few differences between patients of AA and EA, we constructed two coexpression networks oriented to identify critical networks of coexpressed lncRNAs-mRNAs in tumor samples from patients of AA. The results in the first network of DE RNAs in patients of AA showed two tightly connected networks of the same family of genes, TBC1 domain family member and 3 (TBC1D3) and protocadherin alpha (PCDHA). Members of the TBC1D3 family, such as TBC1D3A or PRC7 (prostate cancer gene 17 protein), have been associated with PCa [38]. PCDHA belongs to a subset of a group of cell adhesion molecules, a cadherin superfamily. Yang et al. [39] observed that PCDHA is involved in the EMT axis associated with miR-193a-5p and with p53/RBM25-circAMOTL1. These interesting networks are also present in EA networks (Supplementary Figure 1).
In the second network, where only the coexpression of lncRNAs-mRNAs in patients of AA to a lesser extent than in patients of EA was analyzed, it was observed that mRNAs and lncRNAs were still preserved. Interestingly, two of the upregulated genes (THBSA4 and PCSK6) were coexpressed with their antisense lncRNAs. THBSA4 (thrombospondin 4) was coexpressed with its antisense lncRNA (THBS4-AS1). Liu et al. observed high levels of THBSA4 in PCA and mainly in patients with GS > 7. Cell lines (PC-3 and DU145) were observed to demonstrate reciprocal regulation of the long noncoding RNAs THBS4-003 and THBS4 to control both migration and invasion processes [40]. A recent study demonstrated that the overexpression of THBSA4 promoted self-renewal and proliferation, inhibited the apoptosis of PCa stem cells and enhanced in vivo tumorigenicity, which was achieved by activating the PI3K/Akt pathway [41]. THBSA4 also plays a role in the carcinogenesis of gastric cancer [42] and hepatocellular carcinoma [43]. PCSK6 is another overexpressed gene and is coexpressed with its antisense lncRNA (AC023024.1). PCSK6 is a member of the proprotein convertase family that is involved in PCa carcinogenesis [44] and was recently associated with the proliferation, invasion and migration of breast cancer cells by disturbing cell cycle arrest via the mitogen-activated protein kinase pathway [45]. A coexpression network analysis described the TGFB1I1 mRNA which is a coactivator of the AR that is associated with PCa cell differentiation, and decreased gene expression was observed to be associated with tumor progression [46].

Interestingly, given its high expression in AA and clinical impact, the DNASEL1 gene was noted. This is a member of the DNase 1-like endonuclease family and possesses keratin cell-specific endonuclease activity with an important role in DNA degradation [47]. In a recent study, it was observed that DNASEL1 is upregulated in breast carcinoma, which impacts the EMT process and has relevance in poor overall survival [48].

Conclusion

In the present study, we observed that populations of AA and EA have many similarities in terms of DE lncRNAs and mRNAs and pathway enrichment. We provide a list of DE and coexpressed lncRNAs and mRNAs in both the AA and EA groups. The pathway enrichment analysis revealed two interesting signaling pathways (MAPK and Wnt) that are involved in oncogenesis and are exclusively involved in patients of AA. In the network analysis, lncRNAs and mRNAs were highly coexpressed in AA, and these RNAs have relevance in different pathways related to PCa oncogenesis and have been associated with survival. In summary, this study provides a resource for future investigation of the role of lncRNAs and coexpressed genes in patients of AA and EA.

Summary points

- We observed subtle differences among prostate cancer (PCa) patients of African ancestry (AA) and European ancestry (EA) when we compared transcriptomic dysregulation.
- The pathway enrichment analysis revealed that MAPK and Wnt are involved in oncogenesis and are exclusively involved in patients of AA.
- Two tightly connected networks of the same family of genes (TBC1 domain family member and 3 (TBC1D3) and protocadherin alpha) were expressed in AA. Members of these families have been associated with PCa.
- 24 mRNAs were coexpressed with at least one lncRNAs. Seven mRNAs (CENPN, DNAAF3, DNAE1L2, PCDHB2, PCSK6, RTN4RL2, THBS4) were upregulated. THBSA4 and PCSK6 were coexpressed with their antisense lncRNAs, ENSG00000249825 and ENSG00000259172, respectively.
- Genes differentially expressed or coexpressed as FOXH1, NTM, NPIPB15, DNAE1L2 were associated with poor disease-free survival. And low expression of RNASE4, NUDT7 and SORBS1 served as protective factors for disease-free survival.
- Further studies are required to evaluate a possible role of these mRNA-lncRNA in PCa.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2144/fsoa-2021-0076

Author contributions

Conceptualization: R Parra-Medina, C Payán-Gómez; Methodology, R Parra-Medina, L López-Kleine, S Ramirez-Clavijo, C Payán-Gómez; validation, R Parra-Medina, L López-Kleine, S Ramirez-Clavijo and C Payán-Gómez; investigation: R Parra-Medina and C Payán-Gómez; writing – original draft preparation: R Parra-Medina and C Payán-Gómez; writing – review and editing: R Parra-Medina, L López-Kleine, S Ramirez-Clavijo and C Payán-Gómez; project administration: R Parra-Medina, L López-Kleine, S Ramirez-Clavijo and C Payán-Gómez.
Acknowledgments
The authors would like to acknowledge the TCGA database, which is available for free use.

Financial & competing interests disclosure
This study was supported by the School of Medicine and Health Sciences and the Faculty of Natural Sciences at the Universidad del Rosario. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that for investigations involving human subjects, informed consent has been obtained from the participants involved.

Open access
This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. [Epub ahead of print] (2018).
2. Zeng C, Wen W, Morgans AK, Pao W, Shu X-O, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers. JAMA Oncol. 1(1), 88 (2015).
3. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J. Clin. 69(3), 211–233 (2019).
4. Coughlin SS, Vernon M, Klaassen Z, Tingen MS, Cortes JE. Knowledge of prostate cancer among African American men: a systematic review. Prostate 81(3), 202–213 (2020).
5. Smith ZL, Eggener SE, Murphy AB. African-American prostate cancer disparities. Curr. Urol. Rep. 18(10), 81 (2017).
6. Rebbeck TR. Prostate cancer disparities by race and ethnicity: from nucleotide to neighborhood. Cold Spring Harb. Perspect. Med. 8(9), a030387 (2018).
7. Bhardwaj A, Srivastava SK, Khan MA et al. Racial disparities in prostate cancer: a molecular perspective. Front. Biosci. (Landmark Ed.) 22, 772–782 (2017).
8. Yuan J, Kensler KH, Hu Z et al. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genet. 16(2), 1–26 (2020).
9. Amin N, McGrath A, Chen Y-PP. Evaluation of deep learning in non-coding RNA classification. Nat. Mach. Intell. 1(5), 246–256 (2019).
10. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol. Cell 43(6), 904–914 (2011).
11. Stavast CJ, Erkeland SJ. The non-canonical aspects of microRNAs: many roads to gene regulation. Cells 8(11), 1465 (2019).
12. O’Brien J, Hayden H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne). 9, 402 (2018).
13. Li J, Sun D, Pu W, Wang J, Peng Y. Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends Cancer 6(4), 319–336 (2020).
14. Malik B, Feng F. Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian J. Androl. 18(4), 568–574 (2016).
15. Qin T, Li J, Zhang K-Q. Structure, regulation, and function of linear and circular long non-coding RNAs. Front. Genet. 11, 150 (2020).
16. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct. Target. Ther. 1, 15004 (2016).
17. Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the Pathogenesis of cancers. Cells 8(9), 1–44 (2019).
18. Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Curr. Opin. Genet. Dev. 47, 1033–1055 (2019).
19. Ratti M, Lampis A, Ghidini M et al. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target. Oncol. 15(3), 261–278 (2020).
20. Valera VA, Parra-Medina R, Walter BA, Pinto P, Merino MJ. microRNA expression profiling in young prostate cancer patients. J. Cancer 11(14), 4106–4114 (2020).
21. Parra-Medina R, López-Kleine I, Ramírez-Clavijo S, Payán-Gómez C. Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis. Sci. Rep. 10(1), 1–14 (2020).
22. Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: functional role as biomarkers. *Cancer Lett.* 407, 9–20 (2017).

23. Ramnarine VR, Kobelev M, Gibb EA et al. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. *Eur. Urol.* 76(5), 546–559 (2019).

24. Deng J, Tang J, Wang G, Zhu YS. Long non-coding RNA as potential biomarker for prostate cancer: is it making a difference? *Int. J. Environ. Res. Public Health* 14(3), 270 (2017).

25. Collado-Torres L, Nellore A, Kammers K et al. Reproducible RNA-seq analysis using recount2. *Nat. Biotechnol.* 35(4), 319–321 (2017).

26. Afgan E, Baker D, van den Beek M et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. *Nucleic Acids Res.* 44(W1), W3–W10 (2016).

27. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. *Stat. Appl. Genet. Mol. Biol.* 4(1), Article 17 (2005).

28. Elo LL, Jarvenpaa H, Oresic M, Lahesmaa R, Aittokallio T. Systematic construction of gene coexpression networks with applications to human T helper cell differentiation process. *Bioinformatics* 23(16), 2096–2103 (2007).

29. Shannon P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 13(11), 2498–2504 (2003).

30. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* 45(W1), W98–W102 (2017).

31. Yeh Y, Guo Q, Connelly Z et al. Wnt/Beta-Catenin signaling and prostate cancer therapy resistance. *Adv. Exp. Med. Biol.* 1210, 351–378 (2019).

32. Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. MAP kinases and prostate cancer. *J. Signal Transduct.* 2012, 1–9 (2012).

33. Azzam DG, Tay JWT, Greve MA, Harvey JM, Bentel JM. ERK/MAPK regulation of the androgen responsiveness of breast cancer cells. *Adv. Exp. Med. Biol.* 617, 429–435 (2008).

34. He Y, Mi J, Olson A et al. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis. *Oncogene* 39(16), 3276–3291 (2020).

35. Singh SK, Lillard JW, Singh R. Molecular basis for prostate cancer racial disparities. *Front. Biosci. (Landmark Ed.)* 22, 428–450 (2017).

36. Chen G, Nomura M, Morinaga H et al. Modulation of androgen receptor transactivation by FoxH1. *J. Biol. Chem.* 280(43), 36355–36363 (2005).

37. Rodríguez-Bravo V, Pippa R, Song W-M et al. Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import. *Cell* 174(5), 1200–1215.e20 (2018).

38. Pei L, Peng Y, Yang Y et al. PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. *Cancer Res.* 62(19), 5420–5424 (2002).

39. Yang Z, Qu C-B, Zhang Y et al. Dysregulation of p53-RBM25-mediated circAMOTL1l biogenesis contributes to prostate cancer progression through the circAMOTL1l-miR-193a-5p-Pedha pathway. *Oncogene* 38(14), 2516–2532 (2019).

40. Liu J, Cheng G, Yang H et al. Reciprocal regulation of long noncoding RNAs THBS4-003 and THBS4 control migration and invasion in prostate cancer cell lines. *Med. Mol. Rep.* 14(2), 1451–1458 (2016).

41. Hou Y, Li H, Huo W. THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway. *Prostate* 80(10), 753–763 (2020).

42. Chen X, Huang Y, Wang Y, Wu Q, Hong S, Huang Z. THBS4 predicts poor outcomes and promotes proliferation and metastasis in gastric cancer. *J. Physiol. Biochem.* 75(1), 117–123 (2019).

43. Wu H, Zhang G, Li Z et al. Thrombospondin-4 expression as a prognostic marker in hepatocellular carcinoma. *Gene* 696, 219–224 (2019).

44. Couture F, D’Anjou F, Desjardins R, Boudreau F, Day R. Role of proprotein convertases in prostate cancer progression. *Neoplasia* 14(11), 1032–1042 (2012).

45. Wang P, Wang F, Wang L, Pan J. Proprotein convertase subtilisin/kexin type 6 activates the extracellular signal-regulated kinase 1/2 and Wnt family member 3A pathways and promotes *in vitro* proliferation, migration and invasion of breast cancer MDA-MB-231 cells. *Oncol. Lett.* 16(1), 145–150 (2018).

46. Li S, Lu X, Chi P, Pan J. Identification of Nkx2–3 and TGFB1I1 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy. *Cancer Biol. Ther.* 13(6), 443–449 (2012).

47. Ueki M, Takeshita H, Utsunomiya N et al. Survey of single-nucleotide polymorphisms in the gene encoding human deoxyribonuclease I-like 2 producing loss of function potentially implicated in the pathogenesis of parakeratosis. *PLoS One* 12(4), e0175083 (2017).

48. Liu C-R, Meng F-H. DNASE1L2, as a carcinogenic marker, affects the phenotype of breast cancer cells via regulating epithelial–mesenchymal transition process. *Cancer Biother. Radiopharm.* 36(2), 180–188 (2020).